Targeting IGF-I, IGFBPs and IGF-I receptor system in cancer: The current and future in breast cancer therapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 2, 2011, Pages 166-177

  Mohanraj, Lathika ^a   Oh, Youngman ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anti cancer drugs; Breast cancer; IGF system; IGF IR; IGFBP 3; IGFBP 3R; Patents; Tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; FIGITUMUMAB; PACLITAXEL; PROTEIN TYROSINE KINASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; DRUG TARGETING; ENDOCRINE DISEASE; ENZYME INHIBITION; HUMAN; HYPERGLYCEMIA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASH; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; PATENTS AS TOPIC; RECEPTOR, IGF TYPE 1; RECEPTORS, CELL SURFACE;

EID: 79954531164     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211795328512     Document Type: Article

References (153)

1. Rosenfeld RG, Wilson DM, Lee PD, Hintz RL. Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986; 109: 428-33.
2. Rosenfeld R. Somatomedin Action and Tissue Growth-Factor Receptors. In: Robbins RSM, Ed. Acromegaly: A century of scientific and clinical progress New York: Plenum Press 1987: 45-53.
3. Lowe L. Insulin-like Growth Factors: Molecular and Cellular Aspects. Boca Raton FL: CRC Press 1991: 49-85.
4. Rotwein P. Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 1991; 5: 3-18.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995; 16: 3-34.
6. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulinlike growth factor I. Proc Natl Acad Sci USA 1999; 96: 7324-9.
7. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999; 96: 7088-92.
8. Clemmons DR. Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 2007; 36: 109-29.
9. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
10. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (IGF-1) and type 1 IGF receptor (IGF1R). Cell 1993; 75: 59-72.
11. Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, et al. Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987; 329: 301-7.
12. Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: Similarities and differences in signal transduction. Horm Res 2001; 55: 22-6.
13. Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001; 86: 972-9.
14. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997; 327: 209-15.
15. Mohan S, Baylink DJ, Pettis JL. Insulin-like growth factor (IGF)-binding proteins in serum-do they have additional roles besides modulating the endocrine IGF actions? J Clin Endocrinol Metab 1996; 81: 3817-20.
16. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factorbinding proteins in serum and other biological fluids: Regulation and functions. Endocr Rev 1997; 18: 801-31.
17. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140: 19-24.
18. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: Interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 2000; 278: E967-76.
19. Rechler MM. Insulin-like growth factor binding proteins. Vitam Horm 1993; 47: 1-114.
20. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996; 28: 619-37.
21. Ferry RJ Jr, Cerri RW, Cohen P. Insulin-like growth factor binding proteins: New proteins, new functions. Horm Res 1999; 51: 53-67.
22. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factorbinding protein (IGFBP) superfamily. Endocr Rev 1999; 20: 761-87.
23. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulinrelated ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 535-82.
24. Collett-Solberg PF, Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine 2000; 12: 121-36.
25. Clemmons DR. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev 2001; 22: 800-17.
26. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, et al. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 1995; 270: 20424-31.
27. Qin X, Strong DD, Baylink DJ, Mohan S. Structure-function analysis of the human insulin-like growth factor binding protein-4. J Biol Chem 1998; 273: 23509-16.
28. Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker RH Jr, et al. Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 1997; 138: 362-8.
29. Hasegawa Y, Hasegawa T, Fujii K, Konii H, Anzo M, Aso T, et al. High ratios of free to total insulin-like growth factor-I in early infancy. J Clin Endocrinol Metab 1997; 82: 156-8.
30. Powell DR. Effects of renal failure on the growth hormone-insulinlike growth factor axis. J Pediatr 1997; 131: S13-6.
31. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 1997; 138: 1763-6.
32. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA 1999; 96: 3149-53.
33. Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR. Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: Effects on affinity for IGF-I. Proc Natl Acad Sci USA 1991; 88: 7481-5.
34. Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol 1997; 128: 1-5.
35. Jones JI, Gockerman A, Busby WH, Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 1993; 90: 10553-7.
36. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993; 268:14964-71.
37. Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest 2001; 107(1): 73-81.
38. Radulescu RT. Nuclear localization signal in insulin-like growth factor-binding protein type 3. Trends Biochem Sci 1994; 19: 278.
39. Amaar YG, Thompson GR, Linkhart TA, Chen ST, Baylink DJ, Mohan S. Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem 2002; 277: 12053-60.
40. Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, et al. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA 2003; 100: 13042-7.
41. Oufattole M, Lin SW, Liu B, Mascarenhas D, Cohen P, Rodgers BD. Ribonucleic acid polymerase II binding subunit 3 (Rpb3), a potential nuclear target of insulin-like growth factor binding protein-3. Endocrinology 2006; 147: 2138-46.
42. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000; 275: 33607-13.
43. Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? Cell 1995; 83: 859-69.
44. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
45. Hazel TG, Nathans D, Lau LF. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc Natl Acad Sci USA 1988; 85: 8444-8.
46. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleo-mitochondrial translocation of RXRalpha/Nur77. J Biol Chem 2005; 280: 16942-8.
47. Grimberg A. P53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab 2000; 70: 85-98.
48. Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y, et al. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan. Asian Pac J Cancer Prev 2009; 10: 57-61.
49. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009; 30: 417-37.
50. Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, et al. Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem 2010; 285: 30233-46.
51. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007; 6: 821-33.
52. Chernausek SD. Growth hormone-resistant syndromes: Long-term follow-up. Endocr Dev 2009; 14: 135-42.
53. Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab 2005; 16: 190-7.
54. Mauras N, Beaufrere B. Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995; 80: 869-74.
55. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 1996; 81: 3864-70.
56. Kanda F, Okuda S, Matsushita T, Takatani K, Kimura KI, Chihara K. Steroid myopathy: Pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res 2001; 56 (Suppl 1): 24-8.
57. Khorsandi M, Fagin JA, Fishbein MC, Forrester JS, Cercek B. Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats. Atherosclerosis 1992; 93: 115-22.
58. Zhu B, Zhao G, Witte DP, Hui DY, Fagin JA. Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology 2001; 142: 3598-606.
59. Du J, Peng T, Scheidegger KJ, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol 1999; 19: 2119-26.
60. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest 1992; 90: 439-46.
61. Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990; 10: 464-73.
62. Miura M, Surmacz E, Burgaud JL, Baserga R. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem 1995; 270: 22639-44.
63. Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, Goetsch L. Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007; 43: 1318-27.
64. Catrina SB, Lewitt M, Massambu C, Dricu A, Grunler J, Axelson M, et al. Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br J Cancer 2005; 92: 1467-74.
65. Catrina SB, Botusan IR, Rantanen A, Catrina AI, Pyakurel P, Savu O, et al. Hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha are expressed in kaposi sarcoma and modulated by insulin-like growth factor-I. Clin Cancer Res 2006; 12: 4506-14.
66. Stawowy P, Kallisch H, Kilimnik A, Margeta C, Seidah NG, Chretien M, et al. Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. Biochem Biophys Res Commun 2004; 321: 531-8.
67. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003; 22: 974-82.
68. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65: 3781-7.
69. Samani AA, Brodt P. The receptor for the type I insulin-like growth factor and its ligands regulate multiple cellular functions that impact on metastasis. Surg Oncol Clin N Am 2001; 10: 289-312.
70. Cosaceanu D, Budiu RA, Carapancea M, Castro J, Lewensohn R, Dricu A. Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007; 26: 2423-34.
71. Shahrabani-Gargir L, Pandita TK, Werner H. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 2004; 145: 5679-87.
72. Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079-83.
73. Yu D, Watanabe H, Shibuya H, Miura M. Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem 2003; 278: 6702-9.
74. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999; 56: 1-10.
75. Beech DJ, Perer E, Helms J, Gratzer A, Deng N. Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep 2003; 10: 181-4.
76. Casa AJ, Dearth RK, Litzenburger BC, Lee AV, Cui X. The type I insulin-like growth factor receptor pathway: A key player in cancer therapeutic resistance. Front Biosci 2008; 13: 3273-87.
77. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006; 98: 315-27.
78. Patel AC, Nunez NP, Perkins SN, Barrett JC, Hursting SD. Effects of energy balance on cancer in genetically altered mice. J Nutr 2004; 134: S3394-8.
79. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy. Clin Cancer Res 2007; 13: 1000-9.
80. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: Novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 2009; 4: 54-72.
81. Yakar S, Pennisi P, Kim CH, Zhao H, Toyoshima Y, Gavrilova O, et al. Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models. J Endocrinol Invest 2005; 28: 19-22.
82. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009; 30: 51-74.
83. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005; 12: 90-100.
84. Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989; 84: 1418-23.
85. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280: 19665-72.
86. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgenindependent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065-74.
87. Andrews DW, Resnicoff M, Flanders AE, Kenyon L, Curtis M, Merli G, et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19: 2189-200.
88. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-73.
89. Munshi S, Hall DL, Kornienko M, Darke PL, Kuo LC. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr 2003; 59: 1725-30.
90. Vasilcanu R, Vasilcanu D, Rosengren L, Natalishvili N, Sehat B, Yin S, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and beta-arrestin 1. Oncogene 2008; 27: 1629-38.
91. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66: 362-71.
92. Kurmasheva RT, Boltz C, Phelps D, Morton CL, Houghton PJ. Combination of CP-751871, a human monoclonal antibodyagainst the IGF-1 receptor, with rapamycin results in a highly effective therapy for xenografts derived from childhood sarcomas. AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2007).
93. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007; 26: 1636-44.
94. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulinlike growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 1988; 48: 6429-33.
95. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990; 50: 48-53.
96. Cullen KJ, Allison A, Martire I, Ellis M, Singer C. Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 1992; 22: 21-29.
97. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989; 49: 6237-41.
98. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004; 64: 286-91.
99. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 1990; 50: 6931-5.
100. Novosyadlyy R, Kurshan N, Lann D, Vijayakumar A, Yakar S, LeRoith D. Insulin-like growth factor-I protects cells from ER stress-induced apoptosis via enhancement of the adaptive capacity of endoplasmic reticulum. Cell Death Differ 2008; 15: 1304-17.
101. Zhang X, Lin M, van Golen KL, Yoshioka K, Itoh K, Yee D. Multiple signaling pathways are activated during insulin-like growth factor-I (IGF-I) stimulated breast cancer cell migration. Breast Cancer Res Treat 2005; 93: 159-68.
102. Lynch L, Vodyanik PI, Boettiger D, Guvakova MA. Insulin-like growth factor I controls adhesion strength mediated by alpha5beta1 integrins in motile carcinoma cells. Mol Biol Cell 2005; 16: 51-63.
103. Akekawatchai C, Holland JD, Kochetkova M, Wallace JC, McColl SR. Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005; 280: 39701-8.
104. Maor S, Yosepovich A, Papa MZ, Yarden RI, Mayer D, Friedman E, et al. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 2007; 257: 236-43.
105. Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K, et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer 2007; 14: 1053-62.
106. Mitsui Y, Mochizuki S, Kodama T, Shimoda M, Ohtsuka T, Shiomi T, et al. ADAM28 is overexpressed in human breast carcinomas: Implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res 2006; 66: 9913-20.
107. Brodt P, Reich R, Moroz LA, Chambers AF. Differences in the repertoires of basement membrane degrading enzymes in two carcinoma sublines with distinct patterns of site-selective metastasis. Biochim Biophys Acta 1992; 1139: 77-83.
108. Girnita L, Girnita A, Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 2003; 100: 8247-52.
109. Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001; 8: 325-9.
110. Parisot JP, Hu XF, DeLuise M, Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 1999; 79: 693-700.
111. Nicholson RI, Gee JM. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000; 82: 501-13.
112. Nicholson RI, Staka C, Boyns F, Hutcheson IR, Gee JM. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: New opportunities for therapy. Endocr Relat Cancer 2004; 11: 623-41.
113. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
114. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93: 1852-7.
115. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-28.
116. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999; 18: 2471-9.
117. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63-70.
118. Feng Y, Zhu Z, Xiao X, Choudhry V, Barrett JC, Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006; 5: 114-20.
119. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-80.
120. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, et al. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 2005; 94: 37-46.
121. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, et al. Inhibition of IGF-1R byOSI-9 06 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1. AACRNCIEORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; PR-1.
122. Barr S, Russo S, Buck E, Thomson S, Haley J, Ji QS, et al. The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; A130.
123. Tonra JD, Corcoran E, Li H, et al. Combined antibody mediated inhibition of IGF-IR, EGFR, and VEGFR2 for more consistent and greater antitumor effects. Eur J Cancer Suppl 2006; 4: 64-5.
124. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008; 7: 2589-98.
125. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trialsearly lessons. J Mammary Gland Biol Neoplasia 2008; 13: 471-83.
126. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-203.
127. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulinlike growth factor receptor 1. J Clin Oncol 2009; 27: 5800-7.
128. Higano CS, Yu EY, Whiting SH, Gordon MS, LoRusso P, Fox F. A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. ASCO Meeting Abstracts. 2007; 25(18 suppl): 3586.
129. Atzori F, Tabernero J, Cervantes A, Botero M, Hsu K, Brown HA. Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2008; 26: 3519.
130. Hidalgo M, Tirado GM, Lewis N, Vuky JL, Taylor G, Hayburn JL. A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008; 26: 3520.
131. Moreau P, Hulin C, Facon T, Boccadoro M, Mery-Mignard D, Deslandes A. Phase I Study of AVE1642 Anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. Am Soc Hematol 2007; 110: 1166.
132. Tolcher AW, Patnaik A, Till E, Takimoto CH, Papadopoulos KP, Massard C, et al. A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST). J Clin Oncol 2008; 26: 3582.
133. Rodon J, Patnaik A, Stein M, Tolcher A, Ng C, Dias Cea. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. ASCO Meeting Abstracts 2007; 25 (18 suppl): 3590.
134. Harzstark A, Ryan C, Diamond M, Jones J, Zavodovskaya M, Maddux B. A phase I trial of nordihydroguareacetic acid (NDGA) in patients with non-metastatic prostate cancer and rising PSA. J Clin Oncol 2007; 25 (18 Suppl): 15500.
135. Cohen, B.D., Beebe, J., Miller, P.E., Moyer, J.D., Corvalan, J.R., Gallo, M. Antibodies to insulin-like growth factor I receptor. US7815907 (2010).
136. Camphausen, R., Fabrizio, D., Wright, M.C., Gage, P., Mendleinm J. Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR. US20100121033 (2010).
137. Oh, Y., Rosenfeld, R.G., Buckway, C.K. Mutant IGFBP-3 molecules that do not bind to IGFs, but retain their ability to functionally bind IGFBP-3 receptor. US7714102 (2010).
138. Buck, E.A., Pachter, J.A. Combination anti-cancer therapy. WO2010099139 (2010).
139. Kenneth, D.W., Jain, R. Modulation of growth hormone receptor expression and insulin-like growth factor expression. US7803781 (2010).
140. Clemmons, D.R., Maile, L.A. Method for enhancing or inhibiting IGF-I. US20090226452 (2009).
141. Laeremans, T., De Haard, H., Hoogenboom, H.R.J.M. Nanobodies and polypeptides against EGFR and IGF-IR. US20090252681 (2009).
142. Mayer, S.C., Miller, L.M. 3-Cyanoquinolines, methods for preparation and use as insulin-like growth factor inhibitors. US20090264427 (2009).
143. Ding, Q., Liu, Y., Wu, X., Jin, Q., Che, J., Yan, S.F. Pyrido [4, 3-D] Pyrimidinone derivatives as kinase inhibitors. WO2009099801 (2009).
144. Tarasova, N., Tarasov, S. Synthetic analogs of the juxtamembrane domain of IGF1R and uses thereof. WO2009120993 (2009).
145. Goetsch, L., Corvaia, N., Duflos, A., Haeuw, J.F., Leger, O., Beck, A. Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof. US7553485 (2009).
146. Haley, J.D., Thomson, S. Biological markers predictive of anticancer response to kinase inhibitors. US20080312260 (2008).
147. Lowman, H., Lien, S. IGF binding proteins. US7192738 (2007).
148. Oh, Y., Rosenfeld, R., Ingermann, A.R. Induction of apoptosis and cell growth inhibition by protein 4.33. US20040072285 (2004).
149. Rothenberg ML. Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; C84.
150. Pollak ML, Lacy MQ, Lipton A, Demers L, Leitzel K, de Bano JS, et al., Eds. Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. ASCO Annual Meeting 2007; 3587.
151. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al. Bypassing cellular EGF receptor dependence through epithelial-tomesenchymal-like transitions. Clin Exp Metastasis 2008; 25: 685-93.
152. Demarest, S., Hariharan, K. Anti-IGF-1R antibodies and uses there of. WO2009032145 (2009).
153. Buck, E.A., Eyzaguirre, A., Epstein, D.M., Miglarese, M.R. Combination anti-cancer therapy. US20090263397 (2009).